D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects.
ACS Chem Neurosci
; 11(4): 560-566, 2020 02 19.
Article
em En
| MEDLINE
| ID: mdl-31971364
ABSTRACT
Parkinson's disease is a progressive neurodegenerative disease characterized by striatal dopaminergic loss. L-DOPA treatment replaces lost dopamine and enables motor function; however, eventually, fluctuating efficacy and side effects associated with its use become challenging for many patients. Here, we demonstrate, in a clinically translatable nonhuman primate model of parkinsonian motor symptoms, that treatment with the partial D1 receptor agonist CVL-751, formerly known as PF-06649751, is just as effective as L-DOPA in enabling movement and reducing disability. Importantly, CVL-751 efficacy is observed with less of the concomitant dyskinesia side effect associated with L-DOPA treatment. Data presented suggest that partial D1 agonists may be an effective and important treatment strategy for the management of Parkinson's patients.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Agonistas de Dopamina
/
Doenças Neurodegenerativas
/
Transtornos Parkinsonianos
/
Atividade Motora
Limite:
Animals
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article